CD69和CD25及HLA-DR在川崎病患儿外周血T淋巴细胞中表达的研究

目的研究急性期川崎病(Kawasaki disease,KD)患者外周血CD3+T淋巴细胞中CD69、CD25及HLA-DR的表达水平.方法采用多色流式细胞仪对31例KD急性期、8例KD急性期和恢复期的外周血CD3+T淋巴细胞及其活化标志进行了分析,并以17名正常儿童外周血作为对照.KD组男16例,女15例;年龄4～60个月,平均(26±18)个月.确诊后给予大剂量丙种球蛋白及阿司匹林治疗,丙种球蛋白剂量1g/(kg·d),连续2 d,阿司匹林剂量30～50 mg/(kg·d).丙种球蛋白不反应者(1)重复使用大剂量丙种球蛋白;(2)加用甲泼尼龙20mg/(kg·d),连续3 d.对照组男9名,女8名;年龄3～84个月,平均(25±18)个月.川崎病自身对照组8例,其中男5例,女3例;年龄21～42个月,平均(30±7)个月.结果KD急性期CD3+T淋巴细胞百分数明显低于恢复期及正常对照组,早期(CD69+)、中期(CD25+)活化率明显高于恢复期及正常对照组,丙种球蛋白治疗后,这些活化标志的百分率明显降低(P＜0.01).KD组中冠状动脉改变与冠状动脉正常两组外周血CD3+T淋巴细胞及其活化标志的表达差异无统计学意义(P＞0.05).结论CD3+T淋巴细胞早、中期活化是KD时心血管组织损伤的重要机制.

Changes in CD69, CD25 and HLA-DR expressions in peripheral blood T cells in Kawasaki disease

OBJECTIVE: The study was designed to investigate the changes in CD(69), CD(25) and HLA-DR expressions in peripheral blood T cell in Kawasaki disease (KD). METHODS: The authors detected CD(69), CD(25) and HLA-DR expressions in peripheral blood T cell by using flow cytometry. The patients who met the diagnostic criteria for KD comprised sixteen boys and fifteen girls (4 - 60 months of age; mean, 26 +/- 18 months). All received intravenous gammaglobulin at a dose of 1 g/(kg.d), for 2 days and oral aspirin at a dose of 30 - 50 mg/(kg.d). In case of persistent fever, a repeated dose of intravenous gammaglobulin or I.V. methylprednisolone at a dose of 20 mg/(kg.d) for three daily doses was attempted. The authors tested blood samples from 17 healthy controls consisting of nine boys and eight girls (3 - 84 months of age; mean, 25 +/- 18 months) and the samples from 31 patients. RESULTS: The percentage of peripheral blood CD(3)(+) T lymphocyte was (54.4 +/- 9.0)% in acute stage of KD and (65.0 +/- 7.0)% in healthy controls. There was a significant difference between the two groups (P < 0.001). The values of CD(69)(+) [(11.2 +/- 12.6)%, vs. (0.6 +/- 0.4)%], CD(25)(+) [(9.2 +/- 3.5)% vs. (3.9 +/- 1.8)%] and HLA-DR(+) [(8.3 +/- 5.0)% vs. (4.3 +/- 2.3)%] in KD patients were markedly increased compared to those of the healthy controls. After intravenous gammaglobulin treatment, the percentage of CD(3)(+)CD(69)(+) and CD(3)(+)CD(25)(+) significantly decreased [CD(3)(+)CD(69)(+): (14.0 +/- 13.0)% vs. (1.6 +/- 1.2)%, P < 0.05; CD(3)(+)CD(25)(+): (7.8 +/- 4.1)% vs. (2.0 +/- 0.6)%, P < 0.01]. However, the CD(3)(+) T lymphocytes increased [(50.8 +/- 5.0)% vs. (64.9 +/- 5.5)%, P < 0.01]. There was no significant difference in expression of CD(3)(+) T lymphocyte cell activating markers between coronary artery disease group and normal coronary artery group in KD cases (P > 0.05). CONCLUSION: CD(3)(+) T cell activation in the early and middle stages is involved in the mechanism responsible for cardiovascular injury.